Cancer stem cell-derived extracellular vesicles preferentially target MHC-II–macrophages and PD1+ T cells in the tumor microenvironment
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0279400 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Patricia Gonzalez-Callejo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, Oregon, United States of America. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Head and Neck Neoplasms, Extracellular Vesicles. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, V Foundation for Cancer Research.
Abstract (Originalsprache)
Immunotherapy is an approved treatment option for head and neck squamous cell carcinoma (HNSCC). However, the response rate to immune checkpoint blockade is only 13% for recurrent HNSCC, highlighting the urgent need to better understand tumor-immune interplay, with the ultimate goal of improving patient outcomes. HNSCC present high local recurrence rates and therapy resistance that can be attributed to the presence of cancer stem cells (CSC) within tumors. CSC exhibit singular properties that enable them to avoid immune detection and eradication. How CSC communicate with immune cells and which immune cell types are preferentially found within the CSC niche are still open questions. Here, we used genetic approaches to specifically label CSC-derived extracellular vesicles (EVs) and to perform Sortase-mediated in vivo proximity labeling of CSC niche cells. We identified specific immune cell subsets that were selectively targeted by EV CSC and that were found in the CSC niche. Native EV CSC preferentially targeted MHC-II–macrophages and PD1+ T cells in the tumor microenvironment, which were the same immune cell subsets enriched within the CSC niche. These observations indicate that the use of genetic technologies able to track EVs without in vitro isolation are a valuable tool to unveil the biology of native EV CSC .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, Oregon, United States of America.
- Bionanoplasmonics Group, CIC biomaGUNE, Donostia-San Sebastián, Spain.
- Program in Biomedical Sciences, Oregon Health and Science University, Portland, Oregon, United States of America.
- Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University, Portland, Oregon, United States of America.
- Department of Dermatology, Oregon Health and Science University, Portland, Oregon, United States of America.
- Drug Delivery and Targeting Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- V Foundation for Cancer Research
- EMBO
Zitieren
APA
Gonzalez-Callejo, P., Guo, Z., Ziglari, T., Claudio, N. M., Nguyen, K. H., Oshimori, N., Seras-Franzoso, J., & Pucci, F. (2023). Cancer stem cell-derived extracellular vesicles preferentially target MHC-II–macrophages and PD1+ T cells in the tumor microenvironment. PLOS ONE. https://doi.org/10.1371/journal.pone.0279400
Vancouver
Gonzalez-Callejo P, Guo Z, Ziglari T, Claudio NM, Nguyen KH, Oshimori N, et al. Cancer stem cell-derived extracellular vesicles preferentially target MHC-II–macrophages and PD1+ T cells in the tumor microenvironment. PLOS ONE. 2023. doi:10.1371/journal.pone.0279400
BibTeX
@article{GonzalezCallejo2023,
author = {Gonzalez-Callejo, Patricia and Guo, Zihan and Ziglari, Tahereh and Claudio, Natalie Marcia and Nguyen, Kayla Hoang and Oshimori, Naoki and Seras-Franzoso, Joaquim and Pucci, Ferdinando},
title = {Cancer stem cell-derived extracellular vesicles preferentially target MHC-II–macrophages and PD1+ T cells in the tumor microenvironment},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0279400}
}
EUVIMED